Plasma cell neoplasm

This study tests whether the Gardasil 9 vaccine can help stem cell transplant patients build immunity against HPV. About 48 adults who had a stem cell transplant for blood cancer will receive the vaccine. Researchers will measure antibody levels to see if the vaccine works in the…

This early-phase trial tests whether a vaccine made from a protein called survivin can safely boost the immune system to fight multiple myeloma. The study involves 18 patients who have already responded to initial treatment and are taking lenalidomide as maintenance therapy. The …

This study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This phase 3 trial studies whether taking lenalidomide (Revlimid) after an autologous stem cell transplant can delay the return of multiple myeloma compared to a placebo. About 460 patients with active myeloma who had a stem cell transplant are involved. The main goal is to see h…

This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in adults with multiple myeloma that has come back or is not responding to prior treatments. The goal is to see if this mix can shrink or control the cancer. The trial enrolled 5 participant…

This phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…

This phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…

This study compares two drug combinations—melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR)—in 306 newly diagnosed multiple myeloma patients who cannot have high-dose therapy. The goal is to see which combination better delays cance…

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This phase 3 trial tests whether iberdomide is better than lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer progression longer. The st…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This phase 3 trial tests a new drug, belantamab mafodotin, against a standard treatment (pomalidomide plus dexamethasone) in 325 people with multiple myeloma that has returned or stopped responding to prior therapy. The main goal is to see if the new drug delays cancer progressio…

This study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see…

This study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that t…

This early-phase trial tests a new immune cell therapy called CS1-CAR T cells for people with multiple myeloma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack myeloma cel…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This study compares two versions of the drug teclistamab—one made with the current process and one with a new process—in 108 people with multiple myeloma that has come back or not responded to treatment. The main goal is to see if the body absorbs and handles both versions the sa…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This study tests a new combination of drugs (Dara-SVD) for people with high-risk newly diagnosed multiple myeloma. It compares this new combo to the current standard treatment. The goal is to see if the new approach leads to better cancer control. About 70 participants will take …

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-phase study is testing a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in 14 people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goals are to check safety an…

This early-stage study is testing a combination of two drugs, belantamab mafodotin and feladilimab, in 25 people with relapsed/refractory multiple myeloma who have already tried at least three other treatments. The main goal is to check the safety of the combination and find the …

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This early-phase trial tests a new drug called sotatercept (ACE-011) combined with standard myeloma drugs lenalidomide or pomalidomide and dexamethasone in 33 patients whose multiple myeloma has returned or stopped responding to treatment. The main goal is to find the safest dose…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This early-stage trial is testing a combination of two drugs, belantamab mafodotin and isatuximab, in 30 people with relapsed or refractory multiple myeloma. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have already tried at leas…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This phase 3 trial tests whether a one-time infusion of cilta-cel, a CAR-T cell therapy, works better than standard drug combinations (PVd or DPd) for people with multiple myeloma that has come back and no longer responds to lenalidomide. About 419 participants will be randomly a…

This early-stage trial tests a new treatment called MCARH109 for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses specially modified immune cells to target a protein on the cancer cells. The main goal is to find…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This study was designed to test a new drug called linvoseltamab combined with standard chemotherapy drugs (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if this combination, with or wi…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This phase 2 trial is testing a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and daratumumab) given before and after a stem cell transplant for people with multiple myeloma that has come back after prior treatment. The study includes 41 participants and ai…

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This study is for adults with relapsed or refractory multiple myeloma who have already tried at least three other treatments. It tests a combination of four drugs: belantamab mafodotin, nirogacestat, lenalidomide, and dexamethasone. The goal is to find a safe dose and see how wel…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests a combination of three oral drugs—ixazomib, iberdomide, and dexamethasone—in patients over 70 with multiple myeloma that has returned after initial treatment. The goal is to see how many patients achieve a very good partial response or better. 75 participants wil…

This study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This phase 3 trial compares two treatment combinations for people newly diagnosed with multiple myeloma who are not planning an immediate stem cell transplant. One group gets lenalidomide plus low-dose dexamethasone, while the other gets those two drugs plus bortezomib. The goal …

This study tests a drug called iberdomide as maintenance therapy for people with multiple myeloma who have had a stem cell transplant. The goal is to see if more patients can stay on treatment for at least a year without the disease getting worse. About 40 adults will take iberdo…

This phase 3 trial tests whether a new combination of drugs—belantamab mafodotin, pomalidomide, and dexamethasone—works better than a standard combo for people with multiple myeloma that has returned or not responded to treatment. The study involves 21 Japanese adults who have al…

This phase 3 study tests whether adding the targeted drug belantamab mafodotin to standard medications (pomalidomide and dexamethasone) works better than another standard combo for people with multiple myeloma that has come back or stopped responding to treatment. About 302 parti…

This phase 2 trial tests whether the drug iberdomide, taken after CAR-T therapy, can keep multiple myeloma under control longer than just monitoring. About 78 participants will be randomly assigned to receive iberdomide or standard monitoring. The study is currently suspended.

This early-phase trial tests a new treatment for multiple myeloma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in the lab using CRISPR gene editing to recognize and attack cancer cells. Abou…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This study tests two drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific genetic change called a BRAF V600 mutation. The goal is to see if these drugs can shrink tumors or stop them from growing. The trial includes 44 participants with various c…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study tests whether adding the experimental drug talquetamab to standard treatments (daratumumab and pomalidomide) helps people with multiple myeloma that has returned or stopped responding to prior therapy. About 864 adults will receive either the new combination or the usu…

This study aimed to test a less intense version of a standard four-drug combination (Dara-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if giving one drug (bortezomib) once a week instead of twice could stil…

This study tests a drug called teclistamab in people with multiple myeloma that has come back or stopped responding to treatment. The drug is a special antibody that helps the body's immune cells find and attack cancer cells. About 194 participants will receive the drug to see ho…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This study tests a combination of four drugs (daratumumab, carfilzomib, pomalidomide, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see how many patients achieve tumor shrinkage and how long the benefit …

This study tests a combination of three drugs—isatuximab, pomalidomide, and dexamethasone—at lower doses than usual. It includes 6 patients with multiple myeloma that has returned or not responded to treatment, who are also vulnerable due to age or other health problems. The goal…

This early-phase study tests whether drinking milk from genetically engineered goats (which produce a human enzyme found in breast milk) can reduce the risk of graft versus host disease—a serious immune reaction—in blood cancer patients receiving a donor stem cell transplant. Abo…

This early-stage trial tests combinations of the drug daratumumab with two newer bispecific antibodies (talquetamab and teclistamab), with or without pomalidomide, in 290 people with multiple myeloma. The main goal is to find safe doses and understand side effects. Participants m…

This early-phase study tests a new drug, JNJ-87562761, in 17 people with multiple myeloma whose cancer returned or didn't respond to prior treatments. The main goals are to find a safe dose and check for side effects. Participants must have measurable disease and have tried certa…

This early-phase study is testing a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a drug)—in 11 people with high-risk multiple myeloma that has not responded to prior therapies. The main goal is to check safety and side effects. Researchers will also l…

This phase II trial is testing new therapies, including the drug teclistamab, for people with multiple myeloma that has relapsed or not responded to treatment. About 300 participants will be enrolled in an adaptive platform design that allows adding new treatment arms over time. …

This early-stage trial tests a new drug called talquetamab in 279 people with multiple myeloma that has come back or stopped responding to other treatments. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check sa…

This early-stage study tests a new drug called teclistamab in people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find a safe dose and check for side effects. About 300 participants will receive the drug to see how well it…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This phase 2 trial is testing a drug called elranatamab in 50 people with multiple myeloma that has relapsed or stopped responding after at least one prior treatment. Participants have already tried three main drug classes. The goal is to see if elranatamab can reduce the cancer …

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other treatments will…

This phase 3 trial compares a new CAR-T cell therapy (cilta-cel) plus standard drugs against standard drugs alone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 743 participants will receive either the CAR-T combination or standard …

This early-phase study tests the safety of talquetamab combined with other cancer drugs in 166 people with multiple myeloma, a type of blood cancer. The goal is to find safe doses and check for side effects. Participants must have measurable disease and meet specific lab criteria…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This study is testing a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma. The goal is to see if it can reduce cancer cells to undetectable levels (called minimal residual disease negative). About 210 participants who have already tried oth…

This study is for people newly diagnosed with a standard-risk form of multiple myeloma, a blood cancer. Researchers want to see if giving a sequence of advanced cell therapies (Cilta-cel, Tal-D, Tec-D) after initial chemotherapy can lead to a very deep and lasting remission, poss…

This early-stage study tests whether combining two types of immune-boosting drugs (bispecific antibodies and a checkpoint inhibitor) is safe for people with multiple myeloma that has come back or stopped responding to treatment. About 74 participants will receive either talquetam…

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This study tests whether adding iberdomide (a new oral drug) to standard treatments can eliminate tiny amounts of myeloma cells that remain after a stem cell transplant. About 80 adults with multiple myeloma who still have detectable cancer cells after transplant will receive one…

This phase 2 trial tests the drug ipatasertib in 35 adults with advanced cancers (solid tumors, lymphoma, or multiple myeloma) that have a specific AKT gene mutation. Ipatasertib is an AKT inhibitor designed to block cancer growth signals. The main goal is to see if the drug can …

This phase 2 trial tests a new approach for people newly diagnosed with multiple myeloma who have a high-risk genetic change (P53 abnormality). The treatment combines standard chemotherapy with a double dose of specially engineered immune cells (CAR-T cells) and a stem cell trans…

This study tests a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and isatuximab) in 50 adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see how many patients achieve a complete response after four trea…

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study tests whether adding daratumumab to a standard three-drug regimen (carfilzomib, lenalidomide, and dexamethasone) is safe and effective for people newly diagnosed with multiple myeloma. About 69 participants will receive the four-drug combination for eight cycles, follo…

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This study was designed to test a new type of cell therapy (BCMA-GPRC5D CAR-T) for people with relapsed/refractory multiple myeloma, a blood cancer that had not responded to at least three prior treatments. The goal was to check the treatment's safety and early signs of effective…

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that make cancer cells grow. The trial includes about 10 adults with lymphoma, solid tumors, or multiple myeloma that have not res…

This phase II trial tests the drug palbociclib in 43 patients with advanced cancers that have extra copies of the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to multiply. Researchers will measure how many patients' tumors shrink or stop growing f…

This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…

This phase II trial tests the drug crizotinib in 20 adults with advanced or hard-to-treat cancers that have a specific genetic change called MET exon 14 deletion. Crizotinib is a pill that blocks signals cancer cells need to grow. The study aims to see if the drug can shrink tumo…

This phase II trial is testing the drug afatinib in 19 patients with advanced solid tumors or lymphomas that have a specific EGFR mutation and have not responded to standard treatments. Afatinib works by blocking the mutated EGFR protein that helps cancer cells grow. The study ai…

This phase II trial tests a drug called copanlisib in 35 patients with advanced cancers that have a specific mutation in the PTEN gene. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or slow the disease. The study is small …

This study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…

This phase 2 trial tests the drug vismodegib in 34 patients with advanced solid tumors, lymphoma, or multiple myeloma that have specific mutations in the SMO or PTCH1 genes. Vismodegib works by blocking a protein involved in cell growth. The main goal is to see if the drug can sh…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This early-phase trial aimed to test a new immune cell therapy called BCMA/GPRC5D CAR-T in people with relapsed or refractory multiple myeloma. The study was designed to check safety and dosing, but it was withdrawn before any patients were enrolled. No results are available.

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This phase II trial tests a drug called GSK2636771 in 24 patients whose advanced cancers have a PTEN mutation or deletion. The drug blocks a protein (PI3K-beta) that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from growing.

This study tests an experimental drug called GR1803 in 116 people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see how well the drug shrinks or controls the cancer, and to check its safety. Participants receive the drug for up to 2 y…

This phase II trial tests a drug called GSK2636771 in 35 patients whose cancers have lost a protein called PTEN. The drug blocks a growth signal that these cancers may rely on. Researchers hope to see if it can shrink tumors or stop them from growing.

This early-phase trial tests a new drug called BI 765179, an antibody that helps the immune system fight cancer. It is given alone or with other drugs (ezabenlimab or pembrolizumab) to adults with advanced solid tumors or head and neck cancer. The study aims to find the best dose…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This early-stage trial tests a new drug (CB-839 HCl) combined with two standard treatments for multiple myeloma that has returned or is not responding. The main goal is to find the safest dose and see how well the combination works. About 36 adults with relapsed or refractory mul…

This early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). The drug is thought to make cancer cells more sensitive to radiation, allowing lower doses to be used and potentially reducing har…

This phase II trial tests a combination of eight chemotherapy drugs given in lower doses and shorter cycles to people with high-risk multiple myeloma. The goal is to prevent myeloma cells from regrowing between treatments, leading to longer remissions and better survival. The stu…

This phase 3 trial tests whether a less intense version of a standard chemotherapy regimen can reduce side effects by half while still controlling low-risk multiple myeloma in adults 65 and under. Participants receive a combination of drugs, a stem cell transplant, and three year…

This study tests a combination of four drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) in people with multiple myeloma whose cancer returned or didn't respond after previous treatment with daratumumab. The goal is to see if this combo can shrink tumors more e…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This early-phase trial is testing a combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can help …

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This phase 2 trial is testing a drug called elranatamab in 187 people with multiple myeloma whose cancer has not responded to at least three other types of treatment. The drug works by helping the body's immune cells attack the cancer cells. The main goal is to see how many patie…

This study tests whether the drug iberdomide can safely improve outcomes for people with multiple myeloma who had a less-than-ideal response after a stem cell transplant and previous maintenance therapy. Sixteen participants will take iberdomide and be monitored for disease progr…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This early-stage trial aimed to test the safety and best dose of an experimental oral drug called selvigaltin when added to standard treatments for multiple myeloma that had come back or stopped responding. The study was withdrawn before enrolling any participants, so no results …

This early-phase trial tests a combination of three drugs (elotuzumab, mezigdomide, and dexamethasone) in 12 adults with multiple myeloma that has come back or stopped responding after prior treatments. The goal is to find the safest dose and see how well the body tolerates the r…

This study is for people whose multiple myeloma has returned or stopped responding to at least three prior treatments. Researchers are testing whether adding a lab-modified virus (pelareorep) to a standard drug combination (bortezomib, dexamethasone, and pembrolizumab) can safely…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This phase II trial tests whether radiation therapy can help control cancer that has spread or grown after immunotherapy. About 230 patients with metastatic or lymphoid cancers will receive targeted radiation to see if it stabilizes the disease or shrinks tumors. The study also m…

This study aimed to test a new type of CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that had returned or stopped responding to treatment. The therapy was made from a simple blood draw and took less time to produce than standard CAR-T cells. However, the…

This early-phase study tests a new drug (XmAb24306) combined with another drug (cevostamab) in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. About 90 participants…

This phase 2 trial is testing a combination of four drugs—isatuximab, carfilzomib, lenalidomide, and dexamethasone—in 246 people newly diagnosed with high-risk multiple myeloma. The goal is to see if this intensive regimen can make the cancer undetectable (MRD-negative) and keep …

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This phase 2 trial tests a combination of four drugs (carfilzomib, daratumumab, lenalidomide, and dexamethasone) in 17 people with high-risk multiple myeloma. The goal is to see if the treatment can clear even tiny amounts of cancer left after initial therapy, known as minimal re…

This study tests whether adding daratumumab to standard treatment (bortezomib and dexamethasone) can improve kidney function better than the usual approach (cyclophosphamide, bortezomib, and dexamethasone) in people newly diagnosed with multiple myeloma who also have kidney failu…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This study tests a drug called ulixertinib in people with advanced cancers that have specific changes in the BRAF gene (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that ha…

This study tests a drug called MLN0128 (TAK-228) in 49 adults with advanced cancers that have TSC1 or TSC2 mutations. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if tumors shrink or stop growing, and track how long patients live or stay …

This phase II trial tests the drug MLN0128 (TAK-228) in 35 patients with advanced cancers (solid tumors, lymphoma, or multiple myeloma) that have a specific genetic change called an mTOR mutation. The drug works by blocking enzymes that cancer cells need to grow. Researchers will…

This study tests whether combining two approved drugs, belantamab mafodotin and elotuzumab, is safe and works better than either alone for multiple myeloma. About 24 adults whose cancer has returned or not responded to at least three prior treatments will receive the combination.…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study offers ongoing treatment with the drug CC-122 (Avadomide) to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor long-term safety and serious side effects. Par…

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This study tests a new combination of three drugs—belantamab mafodotin, carfilzomib, and dexamethasone—in people whose multiple myeloma has returned and is no longer responding to lenalidomide. The trial has two parts: first, finding the safest dose, then testing that dose in up …

This phase 2 trial tests a new way of giving chemotherapy to people with high-risk multiple myeloma who have already had some treatment. Instead of high doses with long breaks, researchers give lower doses in shorter cycles to prevent cancer cells from regrowing. The goal is to i…

This study offers continued treatment with isatuximab (a targeted antibody) to adults with multiple myeloma who were already benefiting from it in earlier trials. About 70 participants will receive the drug, possibly combined with other medications, to monitor long-term safety. T…

This phase 2 pilot study tests two new drug combinations—teclistamab plus daratumumab and talquetamab plus daratumumab—in 30 people newly diagnosed with high-risk multiple myeloma. The goal is to see if these treatments can make the cancer undetectable (MRD-negative complete remi…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This study tested two different doses of dexamethasone combined with lenalidomide in 452 people newly diagnosed with multiple myeloma. The goal was to see which dose worked better at shrinking tumors. If the first treatment didn't work, patients could switch to a thalidomide-base…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This phase II trial is testing the drug binimetinib in 53 people whose cancers (excluding melanoma) have a specific genetic change called an NRAS mutation. Binimetinib blocks certain proteins that help these cancer cells grow. The study aims to see if the drug can shrink tumors o…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study looks at whether it is safe to remove one immune-suppressing drug, mycophenolate mofetil (MMF), from the standard treatment plan after a stem cell transplant for blood cancers. Sixty adults aged 18 to 75 will receive the transplant without MMF and be monitored for up t…

This phase 2 trial tests the drug crizotinib in patients with advanced cancers (other than lung cancer) that have a specific genetic change called ALK rearrangement. Crizotinib works by blocking the ALK protein, which may stop cancer cells from growing. The study enrolled only 5 …

This study tests whether a new two-drug combination (teclistamab plus daratumumab) works better than standard three-drug combos for people whose multiple myeloma has returned or stopped responding to treatment. About 587 adults with measurable disease will be randomly assigned to…

This study tests a drug called cevostamab in 90 people with multiple myeloma that has returned or not responded to prior treatments, including BCMA-targeted therapies. Participants receive cevostamab by IV every 3 weeks. The goal is to see if the drug can shrink tumors and how sa…

This early-stage study tests a new type of CAR-T cell therapy, called UWD-00B, for people with multiple myeloma that has come back or not responded to other treatments. The therapy uses donor cells that are modified to target and kill cancer cells, and does not require the patien…

This phase II trial tests the drug trametinib in 35 patients with advanced cancers that have certain BRAF mutations or fusions. The goal is to see if trametinib can shrink or stop cancer growth by blocking proteins that help cancer cells grow. The study focuses on patients whose …

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This study tests a drug called ado-trastuzumab emtansine in people whose cancers have too many HER2 receptors (HER2 amplification), but not breast or stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Researchers want …

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase 2 trial is testing two drug combinations—iberdomide plus dexamethasone, with or without daratumumab—in 140 newly diagnosed multiple myeloma patients aged 65 or older who are not eligible for a stem cell transplant. The goal is to see how well these treatments control t…

This phase II trial is testing the drug defactinib in 35 patients whose advanced cancers have a specific genetic change called an NF2 mutation. The drug works by blocking a protein that may help these cancer cells grow. Researchers want to see if defactinib can shrink tumors or s…

This study is for people with systemic amyloidosis, a disease where abnormal proteins build up in organs. It tests the long-term safety of an experimental drug called AT-02. About 120 adults will receive the drug and be monitored for side effects and how the drug behaves in the b…

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA1 or BRCA2 gene mutation. The drug blocks a protein (WEE1) that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with various adva…

This study tests whether adding isatuximab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who cannot have a stem cell transplant live longer without their cancer worsening. About 475 participant…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This early-stage trial tests an experimental oral drug called ABBV-525 in people with B-cell blood cancers like lymphoma and leukemia. The study aims to find a safe dose and check for side effects. About 78 adults will take the drug in different dose groups over up to 64 months.

This study tests a combination of two drugs, belantamab mafodotin and nirogacestat, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to find a safe dose and see how well the combination shrinks tumors. About 106 ad…

This phase 2 trial tests capivasertib (AZD5363) in 35 patients with advanced cancers that have an AKT mutation. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing.

This study tests a targeted drug called belantamab mafodotin, alone or with other cancer medicines, in people with multiple myeloma that has returned or stopped responding to prior treatments. About 208 adults will take part to see if these combinations are safe and effective. Th…

This study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced…

This study tests the drug selinexor in combination with various standard treatments for multiple myeloma, a type of blood cancer. It involves 300 participants with either relapsed/refractory or newly diagnosed disease. The goal is to find safe and effective doses and to see if th…

This phase II trial tests the drug taselisib in 70 patients with advanced cancers (excluding breast cancer) that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if taselisib can sh…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study compares the drug lenalidomide to simply watching and waiting in people with high-risk smoldering multiple myeloma, a condition that may turn into active cancer. The goal is to see if lenalidomide can delay progression and improve outcomes. About 226 participants were …

This study tests a new way to give a drug called isatuximab as a quick shot under the skin, instead of a long IV drip, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The shot is combined with three standard chemotherapy drugs. The goal is…

This study tests whether adding the investigational drug isatuximab to a standard four-drug regimen can improve outcomes for people newly diagnosed with multiple myeloma. About 52 adults aged 75 or younger will receive the combination before a stem cell transplant. The main goal …

This study tests whether transferring stool from a healthy person into the gut of adults with blood cancers can restore good bacteria lost during chemotherapy. The goal is to reduce dangerous infections and improve quality of life. One hundred participants will be followed long-t…

This phase 2 trial is testing whether leflunomide, a drug used for arthritis, can delay the onset of multiple myeloma in 27 people with high-risk smoldering multiple myeloma. The study includes both African-American and European-American participants to see if the drug works diff…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…

This study planned to test a type of immunotherapy called BCMA CAR-T cells in people with high-risk multiple myeloma who still had signs of cancer after a stem cell transplant. The goal was to see if the treatment could clear remaining cancer cells and improve outcomes. However, …

This study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…

This phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…

This phase II trial tests the drug afatinib in 40 people with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer growth. The study aims to see if the …

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This early-stage trial is testing a new therapy called P-BCMA-ALLO1 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses donor immune cells that are engineered to find and attack myeloma cells. The main goals are to check s…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests a new drug called iberdomide combined with three standard treatments (daratumumab, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to find the best dose and see if the combination can kill more cancer cells. About 49 a…

This study tests a new combination of drugs (belantamab mafodotin, bortezomib, and dexamethasone) against a standard combo (daratumumab, bortezomib, and dexamethasone) in 494 people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if the…

This study tests whether a new combination of drugs—belantamab mafodotin plus bortezomib and dexamethasone—works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people in Japan with multiple myeloma that has come back or stopped responding t…

This Phase 3 trial tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people with multiple myeloma that has come back or stopped responding to t…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread outside the bones, known as extramedullary disease. The goal is to see how well the treatment works and how safe it is. P…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This early-phase study tests a new oral drug called GS-9911, alone or with an intravenous immunotherapy (zimberelimab), in 45 adults with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the best dose, and see how the body handl…

This study tests a combination of two drugs, selumetinib and olaparib, in people with advanced or recurrent solid tumors (including ovarian, endometrial, breast, and others) that have specific genetic changes or have stopped responding to similar treatments. The first phase finds…

This study tests whether the drug isatuximab, given alone or with lenalidomide, can control or shrink the signs of smoldering multiple myeloma in people at high risk of developing active disease. About 61 participants receive the treatment to see if it delays progression and impr…

This phase II trial tests whether adding elotuzumab to standard lenalidomide maintenance therapy can prevent multiple myeloma from returning after an autologous stem cell transplant. About 113 newly diagnosed patients who had a transplant will receive the combination. The goal is…

This study tests a two-part treatment plan for people with multiple myeloma that has come back or is not responding to therapy. First, patients receive daratumumab, bortezomib, and dexamethasone, then switch to daratumumab, ixazomib, and dexamethasone. The goal is to see if this …

This phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 ad…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…

This Phase 3 trial tests whether elranatamab, an immune-boosting drug, works better than lenalidomide at preventing multiple myeloma from returning in patients who have just had a stem cell transplant. About 854 participants will receive either elranatamab injections or lenalidom…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study aimed to see if a special type of stem cell (hAESC) could safely prevent acute graft-versus-host disease in people receiving a stem cell transplant for blood cancer. It was designed for adults at high risk of this complication. However, the study was withdrawn before a…

This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…

This early-phase trial tests a combination of three drugs—bortezomib, gemcitabine, and doxorubicin—in people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the highest safe dose of the two chemotherapy drugs when …

This study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…

This study is testing a new drug called belantamab mafodotin when added to three standard chemotherapy drugs (carfilzomib, lenalidomide, and dexamethasone) for people with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see if this combination ca…

This study is for people with relapsed multiple myeloma who did not get a complete response after CAR-T cell therapy (idecabtagene vicleucel). Researchers want to see if adding nivolumab, an immunotherapy drug, can improve the depth of response. The trial is in Phase 2 and curren…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…

This phase II trial tests the drug trametinib in people whose advanced cancers have specific genetic changes called GNAQ or GNA11 mutations. The drug works by blocking certain proteins that help cancer cells grow. Researchers want to see if trametinib can shrink these tumors or s…

This phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…

This Phase 2 study tests an investigational drug called linvoseltamab in 40 people with high-risk smoldering multiple myeloma, a condition that often leads to active multiple myeloma. The goal is to see if the drug can safely eliminate abnormal plasma cells and prevent the diseas…

This early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …

This study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) as the first treatment for people newly diagnosed with multiple myeloma. The goal is to see how many patients achieve a very deep response, including no detectable cancer cell…

This early-phase study tests a combination of four drugs (cyclophosphamide, pomalidomide, dexamethasone, and daratumumab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination ca…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study is tracking 200 adults with multiple myeloma whose cancer has returned or stopped responding to treatment. They are receiving teclistamab, a drug that helps the immune system find and destroy myeloma cells. Researchers are measuring how many patients respond to the dru…

This early-stage trial tests two new drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets elranatamab (an immune-boosting shot) plus carfilzomib and dexamethasone; the other gets elranatamab plus maplirpacept. The…

This early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This study compares teclistamab (a newer immunotherapy) with two standard drug combinations (PVd or Kd) in about 614 adults whose multiple myeloma has come back or stopped responding after 1 to 3 prior treatments. The main goal is to see if teclistamab helps people live longer wi…

This study tests whether adding lenalidomide (Revlimid) to the standard high-dose melphalan before an autologous stem cell transplant can improve outcomes for people with relapsed multiple myeloma. In the first phase, researchers find the safest dose of lenalidomide to combine wi…

This study tests three different drug combinations containing selinexor (Xpovio) for people whose multiple myeloma has returned or stopped responding to treatment. About 18 adults will receive a combination chosen by their doctor. The goal is to see how well these treatments shri…

This early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researche…

This early-phase trial tests whether a probiotic called CBM588 is safe and can improve outcomes in 36 patients who have received a donor stem cell transplant. The probiotic aims to increase healthy gut bacteria and reduce gut-related side effects like diarrhea and colon inflammat…

This Phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide treatment can help frail older adults with newly diagnosed multiple myeloma live longer without their cancer getting worse. Around 294 participants who are not candidates for h…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new way to do stem cell transplants for 20 children with blood cancers or myelodysplasia who don't have a perfect donor match. Doctors remove certain immune cells from a parent's partially matched stem cells before transplant to help the new cells grow faster a…

This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells (T cells) that are specially trained to recognize and attack cancer cells carrying a protein called MUC…

This Phase 3 trial is testing whether a new combination of drugs—iberdomide, daratumumab, and dexamethasone—can better control multiple myeloma that has come back or stopped responding to treatment, compared to a standard three-drug regimen. About 939 participants who have had 1 …

This study tests a personalized cell therapy called Ide-Cel (CAR T) in people with multiple myeloma who have already had a stem cell transplant. The goal is to see if the therapy can be made successfully and help prevent the cancer from returning. About 24 participants will recei…

This study looks at whether people with multiple myeloma who have no signs of cancer after a stem cell transplant and at least one year of maintenance therapy can safely stop taking their medication. Researchers will use advanced imaging and lab tests to detect even tiny amounts …

This early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 a…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This phase 2 trial tests whether combining belantamab mafodotin (a targeted antibody-drug conjugate) with lenalidomide can eliminate minimal residual disease in multiple myeloma patients who still have detectable cancer after a stem cell transplant. The study enrolls 4 adults who…

This phase 3 study tests whether adding the experimental drug mezigdomide to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with relapsed or refractory multiple myeloma live longer without their cancer getting worse. About 600 participants will be random…

This early-stage trial tests a new drug called BAY2965501, which boosts the immune system to fight cancer. It is given alone or with other drugs like pembrolizumab and chemotherapy. The study includes about 284 people with advanced solid tumors (skin, kidney, stomach, or lung can…

This early-stage trial tests a precise type of radiation (IMTMI) given with chemotherapy before a second donor stem cell transplant for people with advanced blood cancers that have returned. The goal is to find the safest dose and see if it can reduce side effects and prevent the…

This phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response…

This study tests a combination of four drugs (isatuximab, pomalidomide, elotuzumab, and dexamethasone) in people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see how well the drug combo controls the cancer. The st…

This early-phase study tests an experimental drug called etentamig (ABBV-383) in about 55 adults with multiple myeloma that has returned or not responded to prior treatments. The drug is given as a shot under the skin or through an IV. The main goals are to check safety, side eff…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This Phase 2 trial tests whether adding daratumumab to a three-drug regimen (carfilzomib, lenalidomide, dexamethasone) works better than the three drugs alone for people newly diagnosed with multiple myeloma. About 310 participants will be randomly assigned to one of the treatmen…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This early-stage trial tests a new oral drug called cemsidomide (CFT7455) in about 224 adults with non-Hodgkin's lymphoma or multiple myeloma that has returned or not responded to prior therapies. The study aims to find safe doses and check for side effects, both when the drug is…

This phase 2 trial is testing whether adding the targeted drug belantamab mafodotin before and after a stem cell transplant can help people with multiple myeloma achieve deeper remission. About 41 participants will receive the drug alongside standard treatments. The main goal is …

This study tests a combination of four drugs—carfilzomib, lenalidomide, vorinostat, and dexamethasone—in people with multiple myeloma that has relapsed or not responded to prior treatment. The goal is to find a safe dose and see if the combination helps control the cancer. Sevent…

This study tests a new drug called Iberdomide (CC-220) alone or with other cancer drugs in people with multiple myeloma, a type of blood cancer. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors. About 466 participants are invo…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This study tests whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with small cell lung cancer or high-grade neuroendocrine cancers. These cancers often stop responding to standard chemotherapy. The trial includes 37 adults and aims to find t…

This phase 3 trial tests whether a new CAR-T cell therapy (cilta-cel) works better than the standard stem cell transplant for people newly diagnosed with multiple myeloma. About 759 participants will receive either CAR-T or a transplant after initial drug treatment. The main goal…

This study tests an oral enzyme called SYN-004 in adults who have received a stem cell transplant and need intravenous antibiotics for fever. The enzyme is designed to break down antibiotics in the gut, protecting the natural bacteria there. Researchers will check safety, whether…

This phase 2 trial is testing the drug crizotinib in 44 patients with advanced solid tumors, lymphoma, or multiple myeloma that have a specific genetic change called MET amplification. Crizotinib works by blocking enzymes that help cancer cells grow and spread. The main goal is t…

This phase 2 trial tests whether using teclistamab or talquetamab (immune cell redirectors) after initial treatment can improve outcomes for newly diagnosed multiple myeloma. 103 patients receive either teclistamab with lenalidomide or teclistamab with talquetamab, depending on t…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This study tests whether giving patients with high-risk multiple myeloma specially engineered T-cells (CAR T-cells) after a stem cell transplant can safely improve outcomes. The T-cells are designed to target two proteins on myeloma cells, CD19 and BCMA. Researchers are monitorin…

This early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to …

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…

This phase 2 trial tests whether a combination of isatuximab, lenalidomide, and dexamethasone can eliminate minimal residual disease (MRD) in multiple myeloma patients who still have detectable cancer cells after a stem cell transplant. About 30 adults will receive the drug combo…

This study tests whether a lower-dose combination of two drugs (PTCy and ruxolitinib) can prevent graft-versus-host disease (GVHD) in older adults receiving a stem cell transplant for blood cancer. About 56 participants will receive the treatment and be monitored for survival wit…

This study tests two targeted drugs, dabrafenib and trametinib, in people with multiple myeloma that has returned or not responded to treatment. The goal is to see if these drugs can shrink the cancer. About 30 adults will take part in this early-phase trial.

This early-phase trial tests a cancer vaccine (PVX-410) combined with two drugs (citarinostat and lenalidomide) in 19 people with smoldering multiple myeloma, a pre-cancer condition. The goal is to see if the combination is safe and can trigger an immune response against myeloma …

This phase 2 trial tests a combination of four drugs—isatuximab, carfilzomib, pomalidomide, and dexamethasone—in 30 patients with multiple myeloma that has relapsed or become resistant to treatment. The goal is to see how many patients respond to this regimen. All participants ha…

This study tests a CAR-T cell therapy called cilta-cel in 20 people with high-risk smoldering myeloma, an early form of multiple myeloma. The treatment uses a patient's own immune cells, modified to attack cancer cells, along with chemotherapy. The goal is to see if it is safe an…

This Phase II study tests a treatment plan using daratumumab (Darzalex) and dexamethasone for adults aged 65 and older with newly diagnosed multiple myeloma who cannot handle intensive chemotherapy. The goal is to see how well the combination controls the disease by measuring res…

This early-phase trial tests a combination of three drugs (dasatinib, temsirolimus, and cyclophosphamide) in children and young adults with advanced solid tumors that have come back or not responded to standard treatment. The main goals are to find the safest dose and understand …

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…

This study tests a combination of three oral drugs—ixazomib, pomalidomide, and dexamethasone—given twice weekly to people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find a safe and effective dose that controls the cancer. The tri…

This phase 2 trial tests daratumumab (Darzalex) combined with other drugs as a first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. The goal is to see if this combination can achieve very good partial remission or better after 8 cycles, a…

This study follows about 100 people with multiple myeloma who previously received an experimental cell therapy called P-BCMA-101. Researchers will monitor them for up to 15 years to see how safe and effective the treatment remains over time. A safety switch drug called rimiducid …

This study tests whether adding two more drugs (carfilzomib and dexamethasone) to the standard maintenance drug lenalidomide after a stem-cell transplant can keep multiple myeloma from coming back longer. About 180 adults who have already had a transplant and are in stable condit…

This phase 3 trial tests whether a newer three-drug combination (carfilzomib, lenalidomide, dexamethasone, or KRd) works better than the current standard (bortezomib, lenalidomide, dexamethasone, or VRd) for people newly diagnosed with multiple myeloma. About 250 participants wil…

This early-phase trial tests a new treatment for multiple myeloma, a type of blood cancer. It uses a patient's own immune cells, modified to target a protein called BCMA on cancer cells, and may be combined with a drug called lenalidomide. The main goal is to find the safest dose…

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This study tests a new drug called belantamab mafodotin (Blenrep) combined with standard therapy (VRd) in 50 people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if the combination is safe and helps control the disease befor…

This phase 3 trial tests whether adding a CAR T-cell therapy (ide-cel) to standard lenalidomide maintenance can improve outcomes for adults with newly diagnosed multiple myeloma who had a poor response to stem cell transplant. About 79 participants will receive either the combina…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tu…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This phase 2 trial is testing a combination of four drugs—selinexor, bortezomib, dexamethasone, and daratumumab—in 62 patients with multiple myeloma that has returned or not responded to prior treatments. The goal is to see how many patients achieve a significant reduction in can…

This study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Tho…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This trial was designed to test whether a new radioactive imaging agent, 111In-ABD147, could help detect metastatic solid tumors using SPECT/CT scans. It targeted cancers like castration-resistant prostate cancer and high-grade neuroendocrine tumors. However, the study was withdr…

This study looks at whether a new radioactive tracer called PentixaFor can find multiple myeloma lesions more accurately than the standard FDG tracer during PET scans. About 45 adults with symptomatic multiple myeloma, either newly diagnosed or in relapse, will receive both types…

This study tests whether a single urine sample (spot urine) can detect myeloma proteins as accurately as the standard 24-hour urine collection. Researchers will compare results from 180 multiple myeloma patients starting a new treatment. If the spot test works well, it could make…

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests a digital program called MINDSET designed to help newly diagnosed cancer patients cope better with treatment. 440 participants will use either the program or a control, and complete questionnaires and blood tests. The goal is to see if the program improves physic…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This phase 2 trial tests whether combining cognitive behavioral therapy, a stimulant (methylphenidate), melatonin, and light therapy can improve sleep in cancer patients. About 68 patients currently on cancer treatment who have sleep problems will participate. The study measures …

This study tests whether teaching progressive muscle relaxation and providing psychoeducation can lower stress and increase hope in adults with blood cancers like leukemia or lymphoma. About 75 participants will learn these techniques and report their stress and hope levels. The …

This study tests whether a virtual reality (VR) program can help people undergoing bone marrow transplants cope with stress and improve their quality of life. About 80 adult patients with blood cancer will be randomly assigned to either receive the VR program plus usual care, or …

This study tests a mobile app called THRIVE-M designed to help people with multiple myeloma cope with symptoms, emotions, and relationships. About 120 patients will either use the app or receive usual care. Researchers will measure whether the app improves quality of life, reduce…

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…

This study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…

This study tests whether olanzapine, a drug often used for mental health conditions, works better than megestrol acetate (the usual treatment) for improving appetite and preventing weight loss in people with advanced cancer. About 227 adults with cancer-related loss of appetite w…

This pilot study tests whether a daily mindful music listening program is practical and acceptable for patients hospitalized after an allogeneic stem cell transplant. About 35 adults will listen to music for one hour each day using a web-based platform. The study measures how fea…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study tests whether a relaxation breathing exercise can help reduce nausea and vomiting caused by chemotherapy in people with blood cancers. Sixty-eight patients are split into two groups: one does breathing exercises three times a day plus standard care, the other gets stan…

This study looks at how cancer patients feel about using marijuana products (THC or CBD) compared to opioids for pain relief. Researchers will survey 200 adults with cancer-related pain who are already taking strong opioids. The goal is to understand patient preferences and perce…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study will observe 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab as part of their regular care. Researchers will track how quickly the cancer responds, how long the response lasts, and overall survival. The goal is to understand …

This study looks at how spirituality — personal beliefs, values, and meaning — influences adults recently diagnosed with blood cancers like lymphoma or leukemia, as well as their loved ones. Participants fill out three questionnaires about spiritual well-being, quality of life, a…

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. Researchers will study the cells, genes, and proteins in these samples to better understand how these cancers develop and to find new …

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…

This study tests a symptom questionnaire designed for teenagers with cancer. Researchers will interview 41 adolescents aged 13-17 to see if the survey accurately captures their symptoms. The goal is to improve how doctors understand and manage symptoms in young cancer patients.

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…

This study uses bone marrow samples from 70 people with blood cancers to create 3D organoids—tiny lab-grown models that mimic the tumor's environment. Researchers will test different chemotherapy combinations on these organoids to see which kills the most cancer cells. The goal i…

This observational study at Mayo Clinic looks at how immunotherapy drugs affect balance and hearing in cancer patients. Researchers will test 50 adults before and during treatment to see if their vestibular (balance) system changes over a year. The goal is to better understand si…

This pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…

This study planned to check how often the adrenal glands stop working properly after chemotherapy in adults with blood cancers. It aimed to measure cortisol levels after a stimulation test. However, the study was withdrawn before any participants were enrolled, so no results are …

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study looks at how doctors and patients feel about a new approach to picking antibiotics for people with blood cancers who have a reported penicillin allergy. The goal is to understand what might make it easier or harder to use this approach in everyday hospital care. About …

This study aimed to compare a virtual voice agent with a human agent for teaching cancer patients how to use remote monitoring devices at home. Patients with lung cancer would have been randomly assigned to get instructions from either the virtual agent or a human over the phone.…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

This study looks at how well nutritional assessments can detect malnutrition in older adults with cancer. Researchers will follow 180 patients to see if nutrition status is linked to survival at 6 months and 1 year. The goal is to find better ways to identify and address malnutri…

This study observes 357 people with multiple myeloma to see how long it takes for the disease to come back after their first treatment. Participants visit their clinic every 3 months and receive standard care. The goal is to better understand relapse timing in real-life practice,…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study looks at whether cancer patients feel their doctors show more empathy during in-person visits with protective gear (PPE) or during video calls without it. About 107 adults from MD Anderson's emergency center will share their views after a conversation with their doctor…

This study is looking for a better way to predict infection risk in people with chronic lymphocytic leukemia (CLL) or multiple myeloma. Researchers will use advanced lab tests on blood samples from 150 participants to find a biomarker that could warn doctors ahead of time. The go…

This study follows 549 children, teens, and young adults with cancer to see how their immune systems respond to COVID-19 vaccines. Researchers collect blood samples to measure protective antibodies. The goal is to learn how cancer and its treatment affect vaccine effectiveness, a…

This study aims to find out how often cannabis withdrawal happens and how severe it is in patients with blood cancers who are hospitalized for a bone marrow transplant or CAR-T therapy. Researchers will track symptoms like mood changes and physical discomfort using a standard que…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study is not testing a new treatment. Instead, researchers in Italy are observing how doctors currently treat a tough form of multiple myeloma that no longer responds to three main drug classes. They will collect information from medical records of about 250 patients across …

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study follows 500 children and young adults who received gene therapy for cancer as part of earlier trials. Researchers will monitor them for up to 15 years to detect any delayed side effects. Participants have blood tests and health check-ups at regular intervals. No new tr…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study follows 50 young men who had cancer or blood disorders as children and received treatments that can harm fertility. Some stored testicular tissue before treatment; others did not. Researchers will check their fertility through exams, ultrasounds, blood tests, and semen…

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers, how they pr…

This study surveys parents of children with cancer to learn about their attitudes and beliefs regarding the risks of using opioids for pain. Pain is common in pediatric cancer, and opioids are a key treatment, but parents often hesitate or underuse them. The goal is to fill a kno…

This study analyzes tumor and blood samples from 763 people with bone cancer (osteosarcoma) to understand why some tumors resist chemotherapy. Researchers will test how cancer cells respond to drugs in the lab and look for genetic clues. The goal is to learn more about treatment …

This study looks at how the COVID-19 pandemic impacted the quality of life of 274 cancer patients who also have neuropathy (nerve pain). All participants had taken part in earlier clinical trials. Researchers want to see if there are differences between those who received a brain…

This study looks at whether a test called MMprofiler can help doctors decide on the best treatment for people with multiple myeloma, a type of blood cancer. About 250 patients who are candidates for systemic treatment will have their tumor tested, and doctors will fill out questi…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study tests a decision aid website called Pathways to Fertility for women newly diagnosed with cancer who may face infertility from treatment. About 130 women will use the website or receive standard care to see if it helps them make more informed and less conflicted decisio…

This study tests whether personalized telehealth coaching can help young adult cancer survivors become more physically active and improve their diet. Researchers are enrolling 374 survivors aged 18-54 who are not very active. Participants receive one-on-one sessions with a clinic…

This study from MD Anderson Cancer Center surveys 117 advanced cancer patients about whether they've discussed with family how to manage their social media accounts after death. The goal is to understand patient needs and identify sources of stress around digital legacy. Particip…

This study looks at how financial stress affects people recently diagnosed with cancer. Researchers will survey 625 patients to understand what factors contribute to financial hardship. The goal is to identify targets for future programs that could help ease the financial burden …

This study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study takes a small piece of a patient's cancer and grows it in special mice. Doctors then test many different drugs on the mouse tumor to see which ones work best. The results are shared with the patient's oncologist, who decides if and how to use the information. The goal …

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study tests whether a program where older adults (65+) with blood cancer see a team of healthcare providers can help them stay fit and resilient after a stem cell transplant. The program includes health coaching, quality-of-life assessments, and questionnaires. The main goal…

This study looks at how different antibiotics change the friendly bacteria in the gut of people who have had a stem cell transplant and develop a fever with low white blood cells. The goal is to understand which antibiotics are gentler on these helpful bacteria, which may lead to…

This study looks at 69 people with multiple myeloma who had a stem cell transplant. It compares those who take one maintenance drug versus two drugs (an immunomodulatory agent plus a proteasome inhibitor) to see which keeps the cancer away longer. The goal is to learn if the two-…